skip to Main Content
Company Timeline
2007
04
Company founded as Reference Biolabs
2009
03
Corporate R&D lab established
12
Certified as a venture company
2010
08
Registered member of INNOBIZ
09
Approved for ISO 9001 certification
2011
09
Out-licensing deal with Gencurix – breast cancer diagnostics
2012
03
Merger agreement established with Regen Biotech Inc.
12
Merger agreement established with Yeongoonet Inc.
2013
04
Main office relocated to Guro area, Seoul
09
Recipient of SM Business Award for Innovation
2014
06
Renamed company from Reference Biolab to Abion Inc.
07
Listed on KONEX
11
Certified as a family-friendly company by MOGEF
11
Recognized for Laboratory Safety practices by MSIP
2015
01
Awarded Best LMO Research Facility by MSIP
04
Out-licensing deal with GenoBio – CTC diagnostics
08
Out-licensing deal with Oncocross – Therapeutic Anti-Claudin Antibody
08
Awarded KDDF grant to develop ABN101 (Treatment for Multiple Schlerosis)
2016
05
Selected by MOTIE to develop plant-based stem cell growth
08
Awarded KDDF grant to develop ABN401 (Treatment for gastric cancer)
2017
02
Selected by MSIP for Source Technology development project
(Anticancer Antibodies – Interferon – Beta mutein research: ABN201)
03
Selected by Osong Medical Innovation Foundation for R&D project to develop next-generation Interferon – ABN101
06
Selected by the Small and Medium Business Administration for Innovative-Type Technology project
(ABN401 with companion diagnostic system)
2018
04
Selected by MOHW for project on development of Advanced Medical Technology
(ABN401 study for lung and stomach cancers)
04
Selected by MOHW for project on development of Disease Response Technology (SEB Biodefense Vaccine)
2019
Scheduled to enter global Phase I clinical trials for ABN401 & ABN601
Back To Top